TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects ≥18 to ≤55 years of age~* Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm~* Body mass index (BMI) ≥18 and ≤35 kg/sq m~* Willing and able to provide written informed consent~Exclusion Criteria:~* Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing~* Use of any investigational agent or study treatment within 30 days of Day -1~* Use of any protein or antibody-based therapeutic agents within 3 months of Screening~* Prior exposure to LX4211 or canagliflozin~* Daily use of \>5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study~* History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption~* History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying~* History of any major surgery within 6 months prior to Screening~* History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation~* History of renal disease or significantly abnormal kidney function tests~* History of hepatic disease or significantly abnormal liver function tests~* History of any active infection within 30 days prior to Day -1~* History of alcohol or substance abuse within 2 years prior to Day 1~* History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2~* Donation or loss of \>500 mL of blood or blood product within 56 days of Day -1~* positive pregnancy test at Screening or Day -1~* Positive urine screen for drugs of abuse at Screening or Day -1~* Positive breath test for alcohol at Screening or Day -1~* Inability or difficulty swallowing whole tablets~* Unable or unwilling to communicate or cooperate with the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LX4211 (Type: EXPERIMENTAL): 400 mg of LX4211
- Canagliflozin (Type: ACTIVE_COMPARATOR): 300 mg canagliflozin
- Placebo (Type: PLACEBO_COMPARATOR): LX4211 placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with a medical indication for an ovarian stimulation therapy for the purposes of an IVF or ICSI.~* First-time ovarian stimulating therapy for an IVF or ICSI.~* Ovarian stimulation therapy exclusively with Ovaleap®.~* GnRH antagonist protocol.~* Body-Mass-Index (BMI) \< 30 kg/m2.~* Duration of menstrual cycle 24 - 35 days.~  * Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Combined application of IVF and ICSI~* Ovarian hyperstimulation with Ovaleap® with a consecutive social freezing.~* Polycystic ovary syndrome (PCOS).~* Endometriosis (AFS (American Fertility Society) grade 3 and 4).~* Uterine myoma (intramural \> 4 cm, submucosal).~* Hydrosalpinx (on one side or both sides).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ovaleap® (Type: None): Single group prospective treatment cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy;~2. Patients who have previously treated with ≤4 chemotherapeutic regimes;~3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;~4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or more;~5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment;~6. Neuropathy \<CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment;~7. Basically normal results from routine blood test within 1 week prior to enrollment;~8. Basically normal liver and renal functions within 1 week prior to enrollment;~9. No abnormal function for major internal organs, no heart diseases.~Exclusion Criteria:~1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial;~2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE;~3. Patients of pregnancy or breast feeding;~4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period;~5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment;~6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history;~7. Patients with poor compliance;~8. Patients not fitted for this study determined by the investigators.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- UTD1 Injection plus capecitabine (Type: EXPERIMENTAL): UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
- capecitabine (Type: ACTIVE_COMPARATOR): Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of CPVT, based on:~   A. reproducible polymorphic or bidirectional ventricular tachycardia with exercise OR B. Ventricular ectopy on exercise test with RYR2 or CASQ2 mutation~2. Functioning ICD in place~3. On stable dose of standard therapy defined as the maximal tolerated dose of beta-blocker and may include a calcium channel blocker~Patients on flecainide or mexiletine are also eligible for enrollment after a 1 week washout period during which flecainide or mexiletine is discontinued, and standard therapy alone is used.~Exclusion Criteria:~1. Females who are pregnant or plan to be pregnant during the study period~2. Children \< 5 years of age~3. Patients unable to perform treadmill exercise~4. Patients with significant structural heart disease~5. Patients with features consistent with Andersen-Tawil syndrome A. Periodic paralysis or unexplained weakness B. Dysmorphic facies C. Known KCNJ2 mutation~6. Patients with known hypersensitivity to flecainide~7. Patients on amiodarone~8. Patients not expected to comply with follow-up

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Flecainide then placebo (Type: OTHER): In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
- Placebo then flecainide (Type: OTHER): In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be 45 years of age or older at the time of signing the informed consent.~* Participant with AF documented by ECG evidence with~  * CHA2DS2-VASc score ≥ 2 if male or CHA2DS2-VASc score ≥ 3 if female~ * Indication for treatment with an oral anticoagulant in~    * any participant currently not treated with an oral anticoagulant (e.g. treatment naïve) or alternatively,~   * participant on a NOAC in case of at least one bleeding risk feature (history of a prior bleed within the last 12 months requiring medical attention and / or moderate renal dysfunction with eGFR 30-50 ml/min and / or current clinically indicated antiplatelet therapy with Acetylsalicylic acid(ASA) ≤ 100 mg)~* Written informed consent~Exclusion Criteria:~* Mechanical heart valve prosthesis~* Any degree of rheumatic mitral stenosis or moderate-to-severe, non-rheumatic mitral stenosis~* Atrial fibrillation due to a reversible cause, participants in sinus rhythm after successful ablation, or plan for cardioversion or ablation during study conduct~* Requirement for chronic anticoagulation (for a different indication than AF) or antiplatelet therapy (up to 100 mg ASA is allowed). Anticipated need for chronic therapy with Nonsteroidal anti-inflammatory drugs (NSAIDs)~* Treated with a Vitamin K antagonist in the 30 days prior to screening

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY2433334 50mg+Apixaban matching placebo (Type: EXPERIMENTAL): None
- BAY2433334 20mg+Apixaban matching placebo (Type: EXPERIMENTAL): None
- BAY2433334 matching placebo+Apixaban (Type: ACTIVE_COMPARATOR): Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Any gender.~* ASA (American Society of Anesthesiologists) Classification( Class I-II)~* Patients undergoing major elective hepatobiliary surgery.~Exclusion Criteria:~* Preoperative renal failure (GFR \< 50 ml/min).~* Severe liver dysfunction (Child- turcotte -Pugh grade C).~* Hyponatremia (\<132 mmol/l).~* Severe aortic regurgitation, severe mitral regurgitation, heart failure.~* Symptomatic coronary heart disease.~* Bradycardic arrhythmia (heart rate \< 60/min).~* Peripheral artery occlusive disease (clinical stadium II-IV).~* Uncontrolled arterial hypertension (Blood pressure \>160/100 mmHg despite intensive treatment).~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: ACTIVE_COMPARATOR): Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
- CONTROL (Type: PLACEBO_COMPARATOR): Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined as ≤ 6 menses per year). Negative serum pregnancy test at screening. Negative urine pregnancy test before randomisation. Not be breast-feeding. Not have been pregnant within the 6 months prior to screening.~Exclusion Criteria:~Perimenopausal or reached natural menopause, defined as FSH \> 10 IU/L. Menstruated within the month prior to the baseline visit. Hysterectomy or bilateral oophorectomy or both. Clinically relevant disease and abnormalities (past or present), and in particular causes of abnormal vaginal bleeding.~Withdrawals from oral contraceptives if their LH levels are below 3 IU/L when retested within 7 ± 1 days of the baseline visit.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AZD4901 20 mg once a day (Type: EXPERIMENTAL): AZD4901 20 mg once a day
- AZD4901 20mg twice a day (Type: EXPERIMENTAL): AZD4901 20mg twice a day
- AZD4901 40 mg twice a day (Type: EXPERIMENTAL): AZD4901 40 mg twice a day
- Placebo to match AZD4901 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* On a stable dose of insulin as defined by the protocol~* Body mass inde (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular complications~* Laboratory value abnormalities as defined by the protocol~* Other protocol defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pain and stiffness in one shoulder 1 - 6 months~* Restriction of passive ROM; \>= 30 degrees in two or more planes compared to other shoulder~Exclusion Criteria:~* Systemic inflammatory disease~* Corticosteroid treatment last 3 months~* Poorly controlled Diabetes mellitus~* Pregnancy~* Contraindications/allergy to corticosteroids and/or Lidocaine~* Severe infections~* Osteoarthritis of the shoulder~* Fractures of the shoulder~* Rotator cuff pathology causing pain or disability~* Fibromyalgia~* Not able to understand Norwegian

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 capsular & intra-articular (Type: EXPERIMENTAL): corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
- 2 intra-articular (Type: ACTIVE_COMPARATOR): corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
- 3 placebo (Type: PLACEBO_COMPARATOR): placebo injections (Lidocaine) in capsule and intra-articular

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ocular hypertension, primary open-angle glaucoma or pigmentary glaucoma;~* Intraocular pressure (IOP) of between 19 to 35 mmHg at any time of the day in at least one eye (designated as the study eye);~* On a stable medication regimen for IOP reduction one week prior to the screening visit;~* Best corrected visual acuity better than 20/200 (Snellen) or 1.0 (logMAR) in each eye;~* Sign informed consent;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known medical history of allergy, hypersensitivity or low tolerance to any of the components of DuoTrav®;~* Any abnormality that would preclude the reliable performance of applanation tonometry in either eye;~* Infection in either eye;~* Conventional or laser intraocular surgery in either eye 3 months prior to screening visit;~* Risk for visual field or visual acuity worsening, in the opinion of the investigator;~* Women of childbearing potential;~* Pregnant or lactating women;~* Any condition that, in the opinion of the principal investigator, could interfere with participation in the study, or that could present a risk to the participant.~* Participation in another clinical study within 30 days before the screening visit;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 45 years of age or older with Benign Prostatic Hyperplasia (BPH) also referred to as BPH-LUTS \[lower urinary tract symptoms\] based on the disease diagnostic criteria at the start of study.~* Provide signed informed consent at the start of the study.~* Have not taken Finasteride therapy for at least 3 months before study drug is dispensed and Dutasteride therapy for at least 6 months before study drug is dispensed.~* Have not taken other BPH therapy (including herbal preparations), overactive bladder (OAB) therapy, or erectile dysfunction (ED) therapy for at least 4 weeks prior to study drug is dispensed.~* Agree not to use any other approved or experimental pharmacologic BPH, OAB, or ED treatments anytime during the study~* Have LUTS with a Total International Prostate Symptom Score (IPSS) greater than or equal to 13 when study drug is dispensed.~* Have reduced peak urine flow rate when study drug is dispensed (measured by a special toilet equipment).~* Demonstrate compliance with study drug administration requirements.~Exclusion Criteria:~* Treated with nitrates for a cardiac conditions.~* Have unstable angina or angina that requires treatment.~* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).~* Have very high or very low blood pressure~* Have problems with kidneys, liver, or nervous system.~* Have uncontrolled diabetes.~* Have had a stroke or a significant injury to brain or spinal cord.~* Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (Prostate-Specific Antigen \[PSA\] greater than 10 nanograms/milliliter \[ng/ml\] at the start of study).

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete